Ibutilide Administration During Pulmonary Vein Ablation
| Status: | Recruiting |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | October 2007 |
| End Date: | December 2016 |
| Contact: | Antonio Navarrete, MD |
| Email: | annavarr@mac.com |
| Phone: | 765-281-2000 |
Atrial Fibrillation Mechanism Analysis Through Ibutilide Administration During Pulmonary Vein Ablation.
To test the hypothesis that localized functional reentry maintains Afib in humans, ibutilide
will be administered intravenously in patients undergoing an Afib ablation. The hypothesis
of this study is that ibutilide will decrease the high frequency signals observed in Afib
suggesting the presence of micro reentrant circuits as the basic mechanism of Afib,
especially for the paroxysmal Afib group. The potential difference in response to the
ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the
underlying mechanism of Afib between these two groups.
will be administered intravenously in patients undergoing an Afib ablation. The hypothesis
of this study is that ibutilide will decrease the high frequency signals observed in Afib
suggesting the presence of micro reentrant circuits as the basic mechanism of Afib,
especially for the paroxysmal Afib group. The potential difference in response to the
ibutilide in patients with paroxysmal versus persistent Afib may show the difference in the
underlying mechanism of Afib between these two groups.
Inclusion Criteria:
- patients to be scheduled for atrial fibrillation radio frequency ablation
- paroxysmal, permanent symptomatic atrial fibrillation refractory to conventional
treatment
- symptomatic atrial fibrillation that do not want or desire to take medication or
undergo cardioversion
- patients on antiarrhythmics that can be discontinued 5 half lifes prior to the
procedure except for Amiodarone
Exclusion Criteria:
- patients with recent major hemorrhage (within 6 months)
- patients with a coagulopathy
- patients who are pregnant or breast feeding
- patients with acute congestive heart failure
- patients with hypokalemia or hyperkalemia
- patients with a prolonged QTc > 440mms
- patients with polymorphic ventricular tachycardia secondary to antiarrhythmic class
III and class I
- patients with left ventricular dysfunction < 40%
- patients with a history of recent MI (< 1 month)
- patients with a history of an angioplasty of < 1 month
- patients with a history of coronary artery bypass grafting surgery of < 3 months.
- patients with a history of chronic renal failure or a creatinine clearance of <
30ml/m
- patients with a history of stroke of < 6 months
We found this trial at
1
site
Click here to add this to my saved trials
